Janana Snowden, director of the Southern Institute for Medicinal Plants and head of the review committee, had said Med Louisiana's financial strength, expertise in cultivation and proprietary patents made it the top choice.
However, some Southern board members were less impressed. Board member Tony Clayton had said Med Louisiana didn't do itself any favors by skipping the Sept. 7 meeting. He also criticized the company for its lack of black ownership.
Board member Domoine Rutledge said the medical marijuana business offered a great economic development opportunity for north Baton Rouge. But he wondered how Med Louisiana's plan to put the processing facility and its jobs 50 miles away would help the community.
News 
Market Data 
Discover 
AI
